Jewish New Year
Citizenship by Investment
Education in the UAE
Diabetes and Oral Care
India Independence Day
Pakistan Independence Day
Free Zones & Business Setup
Emirates Mars Mission
USA Independence Day
Coronavirus: Sanofi, GSK to start clinical tests of Covid-19 vaccine
French pharma giant says the pre-clinical trials of the vaccine were promising, with an immune response being shown.
French pharmaceutical giant Sanofi on Thursday said it would start human trials of the potential coronavirus vaccine it is developing with British peer GSK, following promising preliminary tests.
The launch of phase 1 and 2 trials represent an "important stage and another step towards the development of a potential vaccine to help us beat Covid-19," said Sanofi Pasteur executive vice-president Thomas Triomphe.
The vaccine combines leading technology from both Sanofi and GlaxoSmithKline.
A protein-based vaccine owned by Sanofi and used to treat influenza was paired with a GSK-developed add-on, known as an adjuvant, that boosts the recipient's immune response.
"The pre-clinical trials show a promising security profile and immunogenity," that is, the ability to bring about an immune response, a Sanofi statement said.
The companies' labs are to recruit 440 healthy participants to carry out tests where neither those tested nor observers know who has received a vaccine and who has been given a placebo.
The tests are designed to evaluate the vaccine's safety, tolerability and immune response.
"Positive data will enable a prompt start of the pivotal phase 3 trial by the end of this year," Roger Connor, president of GSK Vaccines, said in reference to the final step before a vaccine is brought to market.
The firms hope to receive regulatory clearance in the first half of 2021 and take production capacity to a billion doses for distribution throughout the year.
Both say they are committed to making the vaccine available globally.
Several countries have already reserved doses -- with 60 million promised to the British government and 300 million reserved by the European Commission.
The United States has reserved 100 million with an option for up to 500 million more.
Sanofi and GSK have also pledged to make a "significant portion" of 2021/2022 production available to the WHO-led COVAX shared facility designed to guarantee all countries rapid, fair and equitable access to Covid-19 vaccines.
According to the World Health Organization, 75 countries had signed up to using the facility, which would ensure distribution of two billion doses by late July 2021.
Other potential vaccines are even closer to market approval, notably two under development by US giant Pfizer and biotech firm Moderna.
Meanwhile, Sanofi is pursuing a parallel second vaccine attempt in partnership with US-based Translate Bio.
The majority of the Russian capital's residents would be vaccinated... READ MORE
A round-up of major developments related to Covid-19 across the... READ MORE
The health ministry said 1,133 people had died of Covid-19 in the... READ MORE
US President insists 'a wonderful vaccine' will make 'the people of... READ MORE
The Yemeni government will release 681 prisoners while the Houthi... READ MORE
The project aims to offer the UAE space industry with qualified well-... READ MORE
Royal Challengers Bangalore take on Mumbai Indians. READ MORE
Bus services had resumed in Dubai and Sharjah weeks after they were... READ MORE